Prothya BioSolutions produces a wide range of plasma-based pharmaceuticals for patients around the world.
With its production sites in Amsterdam and Brussels, Prothya uses advanced biotechnological methods to compose proprietary pharmaceuticals from blood plasma and offer contract manufacturing and tech transfer services to pharmaceutical companies.
Prothya's pharmaceuticals are used for a large number of disorders, many of which life-threatening
With its production sites in Amsterdam and Brussels, Prothya uses advanced biotechnological methods to compose proprietary pharmaceuticals from blood plasma and offer contract manufacturing and tech transfer services to pharmaceutical companies.
Prothya's pharmaceuticals are used for a large number of disorders, many of which life-threatening
Employees: 201-500
Founded date: 2021
Investors 1
| Date | Name | Website |
| 25.11.2021 | Fortissimo... | ffcapital.... |
Mentions in press and media 1
| Date | Title | Description |
| 25.07.2024 | Syngene Q1 net profit down 19% to ₹75.7 crore | Syngene International Limited, the contract research unit of Biocon, has reported a dip of 19 per cent year-on-year (Y-o-Y) in profit after tax (PAT) from ₹93.4 crore to ₹75.7 crore in the first quarter that ended June 30, 2024. Also read: ... |